The therapeutic efficacy of cell-based therapy after stroke can be enhanced by making the host brain tissue more receptive to the administered cells, which thereby facilitates brain plasticity. We hypothesized that simvastatin increases human umbilical cord blood cell (HUCBC) migration into the ischemic brain and promotes brain plasticity and neurological functional outcome after stroke. Rats were subjected to 2-h middle cerebral artery occlusion (MCAo) and administered subtherapeutic doses of simvastatin (0.5 mg/kg, gavaged daily for 7 days), HUCBCs (1 × 10 6 , one time injection via tail vein), or combination simvastatin with HUCBCs starting at 24 h after stroke. Combination treatment of stroke showed an interactive effect in improvement of neurological outcome compared with simvastatin or HUCBC monotherapy groups. In addition, combination treatment significantly increased brain-derived neurotrophic factor/TrkB expression and the number of engrafted HUCBCs in the ischemic brain compared with HUCBC monotherapy. The number of engrafted HUCBCs was significantly correlated with functional outcome (modified neurological severity score). Combination treatment significantly increased neurogenesis and synaptic plasticity in the ischemic brain, and promoted neuroblast migration in cultured subventricular zone explants. Using primary cultured neurons (PCNs), we found that combination treatment enhanced neurite outgrowth compared with nontreatment control, simvastatin or HUCBC supernatant monotherapy. Inhibition of TrkB significantly attenuated combination treatment-induced neurite outgrowth. Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke.
INTRODUCTION
has been limited by the low migration efficiency and low survival rates of the transplanted progenitor cells in the lesioned area. Therefore, identifying conditions that Human umbilical cord blood cells (HUCBCs) are a rich source of hematopoietic and mesenchymal progeni-enhance HUCBC migration into the ischemic brain and increase the transplanted HUCBC survival is of consid-tor cells, and have potential as a clinical therapeutic agent, since they are easily isolated without ethical and erable clinical interest. Recent data suggest that selected cell-based and phar-technical problems (5, 16, 23, 24) . HUCBCs when administered to ischemic brain proliferate, differentiate, and macological therapies that promote neurogenesis, synaptic plasticity, and axonal outgrowth provide opportunities secrete factors beneficial for the host brain tissue in vivo (29, 30, 34) . However, the effect of HUCBC transplanta-to improve clinical outcomes and brain functional recovery (17, 39, 44) . Statins, 3-hydroxy-3-methylglutaryl-coen-tion is dependent on the number of transplanted HUCBCs (36) , and the success of a vascular route for cell therapy zyme A (HMG-CoA) reductase inhibitors, are a class of 846 CUI ET AL.
drugs originally used to lower cholesterol. Epidemiolog-injected via a tail vein, one time; d) combination simvastatin (0.5 mg/kg, daily for 7 days) and HUCBCs (1 × ical data in a large population of first-ever ischemic stroke patients showed that pretreatment with statins 10 6 ). Immunosuppression with cyclosporine was not performed in the present study, which is consistent with before first-ever ischemic stroke was associated with better early outcome with a reduced mortality during previous studies performed by us and others (5, 30) . Cyclosporine may also affect stroke outcome. Cyclo-hospitalization and neurological disability at hospital discharge (1). Our previous studies have shown that sporine A increases the risk of convulsions in patients with cerebral infarction and/or at an early stage follow-treatment of stroke with an effective dose of simvastatin (1 mg/kg) amplifies angiogenesis and vascular stabiliza-ing focal cerebral ischemia (40) . 5-Bromodeoxyuridine (BrdU, 100 mg/kg/day, Sigma-Aldrich, St. Louis, MO), tion, and promotes arteriogenesis in rats (3, 41, 42) . A subtherapeutic dose of simvastatin (0.5 mg/kg) alone or as a marker for proliferating cells, was injected intraperitonealy 24 h after stroke daily for 14 days. a subtherapeutic dose of bone marrow stromal cells (BMSCs) alone did not improve functional outcome.
Neurological Functional Tests However, a significant increase in the functional outcome was found with combination treatment using a A series of functional tests including a modified neurological severity score (mNSS), adhesive removal test, subtherapeutic dose of simvastatin and BMSCs after stroke in rats (8) . Whether simvastatin promotes and foot-fault evaluation were performed before MCAo and 1, 7, and 14 days after MCAo by an investigator HUCBC migration into the ischemic brain and whether combination treatment of stroke with subtherapeutic who was blinded to the experimental groups, as previously described (5,6). doses of simvastatin and HUCBCs promotes endogenous neurogenesis and synaptic plasticity, and thereby mNSS is a composite of motor, sensory, balance, and reflex tests (5). Neurological function was graded on a augments poststroke restorative therapy have not been investigated. In this study, we investigate the therapeutic scale of 0 to 12 (normal score 0; maximal deficit score 12) with one point awarded for the exhibition of specific benefit of a combination of simvastatin and HUCBCs to amplify the therapeutic effect of HUCBC-based therapy abnormal behavior or for lack of a tested reflex. A greater impairment of normal function results in a higher to improve the functional outcome after stroke in adult rats. We hypothesize that combination treatment pro-score. The adhesive removal test requires the use of adhesive-backed paper dots of equal size (113.1 mm 2 ) motes HUCBC migration into the ischemic brain by increasing brain-derived neurotrophic factor (BDNF) as bilateral tactile stimuli on the distal-radial region of each forelimb (4). Prior to surgery, rats were trained for and its receptor tropomyosin-related kinase B (TrkB) expression within the compromised brain.
3 days to remove the adhesive. Once the rats are able to remove the adhesive dots within 10 s, they were sub-MATERIALS AND METHODS jected to MCAo. Post-MCAo, the time to remove each stimulus from both forelimbs was recorded on three All experiments were conducted in accordance with the standards and procedures of the American Council trials per day. Individual trials were separated by at least 5 min. In the foot-fault test, rats are tested for placement on Animal Care and Institutional Animal Care and Use Committee of Henry Ford Health System. dysfunctions of forelimb (5,6). Rats were placed on elevated hexagonal grids of different sizes. The number of Middle Cerebral Artery Occlusion (MCAo) Model steps used to cross the grid was counted up to 100 steps and Animal Groups or 10 min, whichever came first, and the total number of foot-faults for each forelimb was recorded. Foot-fault Adult male Wistar rats (Jackson Laboratory) weighing 270-300 g were used for inducing a preclinical values were presented as the number of missteps of the contralateral forelimb divided by the total number of stroke model (MCAo). Transient right hemisphere MCAo was induced for 2 h by advancing a 4-0 surgical steps counted. It is well established that in animals with MCAo, the impaired (contralateral) limbs faulted more nylon suture (18.5-19.5 mm) with an expanded (heated) tip from the external carotid artery into the lumen of the often than nonimpaired limbs. internal carotid artery to block the origin of the MCA Lesion Volume Measurement (4). Twenty-four hours after surgery, rats were divided randomly into four groups and treated with: a) phos-Rats were sacrificed 14 days after MCAo by transcardial perfusion with saline, followed by perfusion and phate-buffered solution (PBS, GIBCO), gavaged daily for 7 days; b) subtherapeutic dose of simvastatin (0.5 immersion in 4% paraformaldehyde before being embedded in paraffin (n = 8/group). Seven coronal sec-mg/kg, Sigma), gavaged daily for 7 days (8); c) subtherapeutic dose of HUCBCs (1 × 10 6 , Saneron CCEL Ther-tions of tissue were processed and stained with hematoxylin and eosin for calculation of the lesion volume. The apeutics, Inc., Tampa, FL) in 1 ml of PBS intravenous seven brain sections were traced with the use of the using the MCID imaging analysis system, respectively (7, 8) . Immunostaining and quantitation were performed Global Laboratory image analysis system (Data Translation). To measure the lesion volume, the indirect lesion by an investigator blinded to the experiment. area was calculated, in which the intact area of the ipsi-Enzyme-Linked Immunosorbent Assay (ELISA) lateral hemisphere was subtracted from the area of the contralateral hemisphere. Lesion volume is presented as
To test whether combination treatment regulates BDNF expression in the ischemic brain after stroke, a volume percentage of the lesion compared with the contralateral hemisphere (4,33). Lesion volume was MCAo, simvastatin, HUCBC, and combination treatment animals were killed 3 days after MCAo (n = 4/ measured by blinded manner. group). Brain extracts were obtained from the ischemic Immunohistochemical Assessment border identified visually (bregma −1 to +1 mm, border region encompassing the ischemic core) at 3 days after For immunostaining, a standard paraffin block was obtained from the center of the lesion (bregma −1 to +1 MCAo. Tissue blocks were dissected on ice, and wet weight was rapidly measured. The brain extracts were mm). A series of 6-µm-thick sections was cut from the block. Every 10th coronal section for a total of five sec-divided into 200-µl triplicate samples. Using ELISA kits (R&D Systems, Minneapolis, MN; Calbiochem), BDNF tions was used for immunohistochemical staining. Antibody against BrdU (a marker of proliferating cells, 1:
ELISA was performed. 100; Boehringer Mannheim), doublecortin (DCX, a Subventricular Zone (SVZ) Explant Cell Migration marker of migrating neuroblasts, 1:100; C-18, Santa Cruz Biotechnology), synaptophysin (Syn, a marker of To investigate whether combination treatment increases endogenous SVZ neural progenitor cell (NPC) migra-presynaptic plasticity and synaptogenesis, 1:1000, Chemicon), and anti-human-specific monoclonal nuclear tion, the SVZs derived from MCAo, simvastatin treatment, HUCBC treatment, or combination treatment protein NuMa (1:15; Ab-2, 107-7, EMD Chemicals) (9, 22) , BDNF (1:300, Santa Cruz), and TrkB (1:500, animals 7 days after MCAo (n = 4/group) were dissociated. The SVZ explants were cut to 1-mm 3 sections and Santa Cruz)) immunostaining was performed. In addition, Bielshowsky silver and Luxol fast blue (LFB) histohemi-plated in BD Matrigel TM Matrix (BD Biosciences, Bedford, MA) in 24 wells (6 wells each group) with 1 ml cal stainings were used to identify axons and myelin, respectively, as previously described (7) . Control experi-of Neuralbasal-A medium (Invitrogen) containing 2% of B27 supplement (Invitrogen). For specific measurement ments consisted of staining brain coronal tissue sections as outlined earlier, but omitted the primary antibodies.
of SVZ-NPC migration, DCX (a marker of migrating neuroblast, 1:250, Santa Cruz) immunofluorescent con-Immunostaining Quantitation jugated with Cy3 staining was performed and the cell migration length was measured at 5 days after culture. For quantification of NuMa, BrdU, DCX, BDNF, synaptogenesis, Bielshowsky silver, and LFB immuno-
The 4× objective with 1.5× electronic zoom of an Olympus IX71 microscope with a CCD camera (CoolSNAP, staining, five slides from the standard reference coronal section of each brain, with each slide containing eight Proper Scientific Photometrics) and Meta View software (Universal Imaging, West Chester, PA) were used for fields from the ischemic border zone (IBZ, adjacent to the ischemic core area), were digitized under a 40× acquiring images. The average distance of DCX-positive cell migration from the explant culture edge was mea-objective (BX40; Olympus Optical) using a 3-CCD color video camera (DXC-970MD, Sony) interfaced sured by an investigator blinded to the explanted culture using the Meta View software. with a Micro Computer Imaging Device (MCID) software (Imaging Research). For quantitative measure-Primary Cultured Neuron (PCN) and Neurite ments, the total numbers of NuMa-positive human cells Outgrowth Measurement (HUCBCs) both in the ischemic ipsilateral and contralateral brain hemisphere, the percentage number of BrdU-To test whether combination treatment increases dendrite outgrowth and whether the mechanisms underlying positive cells in the subventricular zone (SVZ), and the percentage number of the DCX-positive neuroblasts the enhanced neurite outgrowth are mediated by the BDNF/TrkB pathway, PCN culture was employed and both in the SVZ and in the ischemic ipsilateral striatum were measured. For quantitative synaptophysin, BDNF, oxygen-glucose deprivation (OGD) was induced in vitro, as previously described (7) . Briefly, embryonic and TrkB expression, and Bielshowsky silver and LFB, the percentage of synaptophysin-, BDNF-, and TrkB-day 17 (E17) cortical cells were isolated from embryonic brain of Wistar rats and cultured in four-chamber positive area in the IBZ, and the percentage of Bielshowsky silver-and LFB-positive areas in the bundle of slides with Neuralbasal-A medium (GIBCO) containing 2% B27 medium supplement (GIBCO) and antibiotics stratum in the IBZ were also measured in each section for 7 days. To mimic the ischemic condition in vivo, effect on foot-fault test 14 days after MCAo (F = 8.5, p < 0.01); HUCBC monotherapy showed significant OGD was induced within an anaerobic chamber (model 1025, Forma Scientific) by 85% N 2 , 10% H 2 , and 5% functional benefits both on foot-fault test (7 days: F = 39.1, p < 0.01; 14 days: F = 44.0, p < 0.01) and adhe-CO 2 , at 37°C for 1 h. The PCN cultures were removed from the anaerobic chamber and rinsed with PBS. The sive-removal test (7 days: F = 22.5, p < 0.01; 14 days: F = 20.3, p < 0.01) after stroke. However, statistically PCN cultures were divided into six groups, six chambers each group with 0.5 ml medium: 1) nontreatment for significant effects of simvastatin monotherapy (7 days, F = 15.6, p < 0.01; 14 days: F = 21.8, p < 0.01) and control; 2) + simvastatin 1 µM; 3) + HUCBC supernatant (0.5 ml); 4) + simvastatin + HUCBC supernatant;
HUCBC monotherapy (7 days, F = 27.4, p < 0.01; 14 days: F = 36.9, p < 0.01) and a positive interactive effect 5) BDNF 50 ng/ml; 6) simvastatin + HUCBC supernatant + TrkB inhibitor (K252a, 200 nM, Calbiochem, of them (14 days: F = 7.3, p < 0.05) on mNSS after stroke were confirmed by two-way ANOVA (Fig. 1A) . Cat# 480354), for 24 h. Then the PCN cultures were performed for neuron-specific class III β-tubulin (TUJ1,
These data indicate that combination treatment of stroke significantly improves functional outcome after stroke. a phenotypic marker of neural cells) immunofluorescent staining using a monoclonal anti-TUJ1 antibody Lesion Volume in the Ischemic Brain (Covance, 1:1000) with Cy3 for PCN number counting and neurite outgrowth measurement (7, 14) . Figure 1B shows a significant decrease in the ischemic lesion volumes 14 days after stroke in HUCBC To trace the axonal arbors of fluorescently labeled neurons, the fluorescent photomicrographs were cap-treatment alone and combination groups without interaction with simvastatin treatment compared with the tured at 40× magnification with a digital camera, the TUJ1-positive PCN numbers and the length of TUJ1-MCAo control group (p < 0.05, n = 8/group). positive dendrites were measured using MCID analysis Combination Treatment of Stroke Significantly system (27) . The average number of TUJ1-positive Increases the Number of Engrafted HUCBCs PCNs per 40× field and the average length of total 20
in the Ischemic Brain neuronal dendrite outgrowths were presented. Neurite outgrowth was measured by blinded manner. Figure 1C shows that there is a significant increase in the number of NuMu-positive HUCBCs in the ipsilateral Statistical Analysis hemisphere in the combination treatment rats compared Two-way ANOVA (univariate or multivariate analyto HUCBC monotherapy rats (p < 0.05, n = 8/group). In sis of variance) with +/− Simvastatin and +/− HUCBC addition, the immunostaining images showed that as two of the factors was used for analyzing the data of NuMu-HUCBCs primarily aggregated around the vascufunctional evaluation, lesion volume, BrdU, DCX, synlar vessels in the ischemic area of the brain. Figure 1D aptophysin, Bielshowsky silver, LFB, BDNF/TrkB shows that the increased number of HUCBCs in the immunostaining, and neuroblast migration in SVZ, and ischemic brain is significantly correlated with the one-way ANOVA was used for neurite outgrowth in improvement of mNSS test (r = −0.751, p < 0.05).
PCN. Post hoc test (Tukey) was used for multiple com-
These data indicate that combination treatment of stroke parison if an overall treatment group effect was detected significantly increases the number of engrafted HUCBCs at p < 0.05. Independent two-sample t-test was used for in the ischemic brain as well as promotes functional outtesting the number of NuMa-positive HUCBCs that come after stroke. The numbers of HUCBCs present in migrate into the ischemic ipsilateral and contralateral the ischemic brain may contribute to improved funcbrain between two groups. Pearson partial correlations tional recovery after stroke. after bivariate correlation were used to analyze the cor-Combination Treatment of Stroke Significantly relation of the engrafted HUCBC number in the ische-Increases NPC Proliferation and Migration mic brain with the neurological functional outcome (i.e., in the Ischemic Brain mNSS, adhesive removal, and foot-fault test, respectively). All data are presented as mean + SE.
Neurogenesis is related to functional recovery after stroke (18) . The rostral SVZ is one of neuroproliferative RESULTS regions in adult animals, and the NPCs generated in the Combination Treatment of Stroke Significantly SVZ migrate to the ipsilateral striatum after injury (20) . Improves Neurological Outcome Figure 2A -E shows that the percentage of BrdU-positive cells in the SVZ significantly increased in simvas-Two-way ANOVA analysis did not reveal a significant interaction between simvastatin and HUCBC mon-tatin treatment alone and combination treatment groups compared with MCAo control group (p < 0.05, n = 8/ otherapy on adhesive removal and foot-fault test. Instead, simvastatin monotherapy showed a significant group). Figure 2F -J shows that simvastatin, HUCBC, and combination treatment groups significantly increased treatment of stroke induces synaptic plasticity and axon growth, synaptophysin, Bielschowsky silver, and LFB DCX neuroblast cell numbers in the SVZ compared with MCAo control group (p < 0.05, n = 8/group). There was immunostaining were performed. Synaptophysin is a marker for presynaptic plasticity and synaptogenesis no interaction for simvastatin and HUCBC monotherapy on BrdU or DCX cells in the SVZ. However, a signifi- (35) . Bielschowsky silver is a marker for axons (21, 31) . LFB is a marker of myelin. Figure 3A -E displays that cant main effect for simvastatin (F = 5.5, p = 0.028) or HUCBC monotherapy (F = 26.3, p < 0.01) and a signifi-HUCBC monotherapy did not increase synaptophysin.
Simvastatin monotherapy significantly increased synap-cant interaction effect (F = 5.2, p = 0.032) in DCX neuroblast numbers in the ischemic striatum were found. tophysin expression in the bundles of the IBZ (F = 16.9, p < 0.01). Moreover, there was a positive interaction These data indicated that combination treatment of stroke significantly enhanced endogenous NPC genera-between simvastatin and HUCBC monotherapy (F = 10.0, p < 0.01). Figure 3F -J shows that simvastatin tion in the ipsilateral SVZ and increased SVZ neuroblast migration into the ischemic ipsilateral striatum.
(F = 64.8, p < 0.01) and HUCBC monotherapy (F = 32.6, p < 0.01) significantly increased Bielshowsky Combination Treatment of Stroke Increases Synaptic silver axon density in the IBZ compared with MCAo Plasticity and Axon Growth in the Ischemic Brain control. However, combination treatment displayed a significant interaction between the two monotherapy Synaptic plasticity and axonal growth promote functional outcome after stroke. To test whether combination groups (F = 8.3, p = 0.007). In addition, the correlation analysis showed there was a significant correlation of increased synaptic plasticity and axonal growth after stroke, which may also contribute to the functional bene-synaptophysin staining in the ischemic brain with mNSS (r = −0.77, p < 0.05). Figure 3K -O shows that simvas-fit after stroke. tatin treatment alone significantly increased LFB myelin in the bundles of the IBZ compared with MCAo control Combination Treatment of Stroke Increases BDNF (p < 0.05, n = 8/group). HUCBC treatment alone did not and TrkB Expression in the Ischemic Brain increase LFB myelin; however, there was a significant increase when combined with simvastatin (F = 6.6, p = BDNF/TrkB play an important role in neuronal survival, differentiation, synaptic plasticity, and neurogen-0.016) measured by two-way ANOVA. These data indicated that combination treatment of stroke significantly esis, and enhance functional recovery after brain injury (10). To test the molecular mechanism of combination-Combination Treatment of Stroke Increases Ipsilateral SVZ Neuroblast Migration In Vitro induced brain plasticity, immunostaining for BDNF/ TrkB was performed. Fig. 4A -K shows that simvastatin or HUCBC treatment alone significantly increased To further investigate whether combination treatment increased neurogenesis, the ipsilateral SVZ BDNF and TrkB expression in the ipsilateral IBZ compared with MCAo control (p < 0.05, n = 8/group). A explant cultures derived from animals were employed. Figure 5A and B shows that simvastatin treatment and positive interactive effect of combination simvastatin and HUCBC treatment on BDNF (F = 9.2, p < 0.01) and
HUCBC treatment significantly enhanced DCX neuroblast (simvastatin: F = 68.3, p < 0.01; HUCBC: F = TrKB (F = 6.31, p = 0.018) was confirmed by two-way ANOVA. To further verify whether single or combina-85.6, p < 0.01) migration in the SVZ explant cultures compared with MCAo alone group. However, combi-tion treatment upregulates BDNF, ELISA assay of the ipsilateral brain tissue was also employed. Figure 4F nation treatment displayed a significantly interaction effect on DCX neuroblast migration (F = 14.1, p < shows that HUCBC treatment significantly increased BDNF protein level measured by ELISA assay com-0.01) compared with simvastatin or HUCBC treatment alone, respectively. pared with MCAo control group (p < 0.05, n = 4/group). 
in PCN Cultures
To further investigate the molecular mechanism of DISCUSSION the combination treatment increase of axonal growth after stroke, PCN neurite outgrowth measurement was HUCBCs can be used for autologous or allogeneic transplantation (32, 37) . Compared with BMSCs, HUCBCs performed. Figure 5C -I shows that simvastatin (1 µM), HUCBC supernatant, and BDNF (50 ng/ml) signifi-are less mature than BMSCs and can be successfully used even when there is only a half-match of acceptors. cantly increased neurite outgrowth (TUJ1 staining of βIII tubulin) compared with nontreatment control. More-Transplantation of a human umbilical cord bloodderived neural-like stem cell line (HUCB-NSCs) in a rat over, combination simvastatin and HUCBC supernatant significantly increased neurite outgrowth compared with model of cortical infarct shows HUCB-NSC survival and extensive migration into damaged brain and some simvastatin or HUCBC supernatant monotreatment differentiation to neurons and astrocytes (24). HUCBCs BDNF (15) . In the present study, combination treatment of stroke showed a significant upregulation of BDNF/ when administered intravenously selectively migrate to the ischemic area in the brain and enhance functional TrkB and synaptophysin expression as well as an increase of axonal growth in the ischemic brain. In vitro recovery after stroke (5). Therefore, the intravenous treatment with HUCBCs may be a convenient strategy study also showed that combination treatment significantly increased SVZ explant NPC migration and PCN for clinical treatment of stroke patients. In the present study, we show that combination treatment with neurite outgrowth. However inhibition of TrkB attenuated neurite outgrowth induced by combination treat-HUCBC and simvastatin significantly increased the number of engrafted HUCBCs in the ischemic brain, and ment. Our previous study also found that BDNF promotes SVZ explant cell migration, and inhibition of improved functional outcome after stroke.
Stroke results in increases in neurogenesis in the SVZ BDNF by using anti-BDNF neutralizing antibody significantly inhibited SVZ explant cell migration (6) . These in adult brain, which might be an endogenous attempt to self-repair (43) . Increasing neurogenesis decreases data support our hypothesis that the BDNF/TrkB pathway promotes neurogenesis and synaptic plasticity and cognitive and behavioral deficits following stroke (25) . Neurogenesis consists of two processes: NPC prolifera-axon growth after stroke. In summary, our data demonstrate that combination tion in the neuroproliferative regions and migration into lesioned area (2). In the present study, we found that simvastatin and HUCBC treatment of stroke significantly upregulates BDNF/TrkB, enhances HUCBC combination treatment of stroke significantly increased the number of BrdU-proliferating cells in the SVZ and intracerebral transplantation, and increases neurogenesis, synaptic plasticity, and axon growth in the ischemic also significantly increased the number of migration neuroblasts in the neighboring striatum, ipsilateral to the brain, which improve neurological functional recovery after stroke in rats. These studies have important impli-lesion. The increased neurogenesis is consistent with the benefit of functional outcome seen in the combination cations for the restorative use of cell-based therapy, and provide a basis for priming brain with pharmacological treatment animals. Our data also showed that combination treatment of stroke with subtherapeutic doses of agents to amplify the therapeutic effect of cell-based treatment of neurological disease. simvastatin and HUCBCs failed to induce a significant interactive effect in lesion volume, foot-fault, and adhe- outgrowth. Therefore, combination treatment of stroke with subtherapeutic doses of simvastatin and HUCBCs REFERENCES significantly enhanced neurogenesis, synaptic plasticity, and axon growth, which may, in concert, mediate func-
